Abstract
Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome (HGPS), a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae. The US Food and Drug Administration approved Zokinvy™ (lonafarnib) in November 2020 for treating these patients, yet a detailed examination of drug-associated effects on cardiovascular structure, properties, and function has remained wanting. In this paper, we report encouraging outcomes of daily post-weaning treatment with lonafarnib on the composition and biomechanical phenotype of elastic and muscular arteries as well as associated cardiac function in a well-accepted mouse model of progeria that exhibits severe end-stage cardiovascular disease. Lonafarnib resulted in 100% survival of the treated progeria mice to the study end-point (time of 50% survival of untreated mice), with associated improvements in arterial structure and function working together to significantly reduce pulse wave velocity and improve left ventricular diastolic function. By contrast, dual treatment with lonafarnib and rapamycin did not improve outcomes over that achieved with lonafarnib monotherapy.
Introduction
Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare genetic condition characterized by "accelerated aging." Children with HGPS typically die in their early teens from cardiovascular complications, most notably heart failure and stroke. The root cause of this pathology is the accumulation of progerin, a toxic, farnesylated version of the nuclear protein lamin A. Progerin disrupts cellular integrity, particularly within the vascular smooth muscle cells, leading to severe arterial stiffening and cardiac dysfunction.
While the farnesyltransferase inhibitor Lonafarnib (Zokinvy™) was recently FDA-approved based on its ability to extend patient lifespan, the specific biomechanical mechanisms by which it protects the cardiovascular system have not been fully elucidated. This study utilizes a robust mouse model to perform a comprehensive analysis of the structural and functional changes in the heart and arteries under Lonafarnib treatment.
Methods
Experimental Model
The researchers utilized the $Lmna^{G609G/G609G}$ (GG) mouse model, which closely mimics the human HGPS phenotype. The study compared three primary cohorts: wild-type (WT) mice, untreated progeria mice (GG), and progeria mice treated with Lonafarnib (GG+L) administered daily in a soft gel-based chow starting at weaning.
Cardiovascular Assessment
To capture the multi-scale effects of the treatment, the team employed several high-resolution techniques:
- Biaxial Biomechanical Testing: A custom computer-controlled device measured the stiffness and vasoactivity (constriction and dilation capacity) of the aorta (an elastic artery) and the mesenteric artery (a muscular artery).
- High-Resolution Echocardiography: This assessed cardiac performance, focusing on both systolic (pumping) and diastolic (filling) metrics.
- Histology and Compositional Analysis: Specialized stains (Movat Pentachrome and Alizarin Red) quantified the accumulation of proteoglycans and medial calcification within the vessel walls.
- Pulse Wave Velocity (PWV): Calculated using the Moens-Korteweg relation, PWV served as the primary metric for global arterial stiffness.
Key Insights and Results
Survival and the "Perimorbid Cliff"
One of the most striking findings was the identification of a "perimorbid cliff" in untreated mice. Between 140 and 168 days, untreated GG mice experienced an exponential decline in arterial health, characterized by rapid stiffening and brittle calcification. Lonafarnib treatment effectively prevented this terminal decline. By the study's endpoint (168 days), 100% of Lonafarnib-treated mice survived, compared to only 53% of the untreated group.
Biomechanical Synergy and PWV Reduction
The study highlights that Lonafarnib does not necessarily "cure" any single vascular metric. Instead, it provides modest, simultaneous improvements across several parameters: wall thickness, luminal radius, and material stiffness. Because these factors are multiplicative in the physics of hemodynamics, their combined effect resulted in a significant 36.5% reduction in Pulse Wave Velocity (PWV). Treated mice showed a PWV of 10.3 m/s, a marked improvement over the 16.2 m/s seen in untreated mice (WT baseline is ~5.3 m/s).
Differential Effects on Elastic and Muscular Arteries
The drug's impact varied by vessel type:
- Elastic Arteries (Aorta): Lonafarnib primarily improved structure, significantly reducing the accumulation of mural proteoglycans and medial calcification.
- Muscular Arteries (Mesenteric): The drug rescued function, largely preventing the total loss of vasoconstrictive and vasodilatory capacity that typically occurs in the disease state.
Cardiac Diastolic Rescue
While systolic function (the heart's ability to pump blood) remained relatively stable in the progeria model, diastolic function (the ability to relax and fill) was severely compromised. Lonafarnib significantly improved the filling velocity of the left ventricle, suggesting that the survival benefit is driven by a combination of reduced afterload (lower arterial stiffness) and improved cardiac relaxation.
Discussion and Future Directions
Combination Therapy Observations
The study also explored a combination therapy of Lonafarnib and Rapamycin (an mTOR inhibitor). Despite previous cell-culture studies suggesting synergy, the combination actually decreased survival in this model. The authors hypothesize this may be due to the stress of daily intraperitoneal injections in frail, progeroid animals, suggesting that oral delivery methods for combination therapies require further investigation.
Limitations
The researchers noted that this study did not assess the coronary arteries or the microcirculation within end-organs, which remain critical areas for understanding HGPS-related mortality.
Conclusion
Lonafarnib acts as a vital cardiovascular stabilizer by improving the structural and functional properties of the arterial tree. While it significantly extends survival and slows the progression of the disease, the authors conclude that future breakthroughs will likely require genetic editing or RNA-based therapies to fundamentally reverse the progeroid phenotype. Nonetheless, these findings provide a biomechanical foundation for the clinical success of Lonafarnib in human patients.
Summary updated